about
Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic reviewSelective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study.A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer.Volumetric CT-based segmentation of NSCLC using 3D-SlicerImpact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineationAssessment of tumour size in PET/CT lung cancer studies: PET- and CT-based methods compared to pathology.The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning.A prospective study comparing the predictions of doctors versus models for treatment outcome of lung cancer patients: a step toward individualized care and shared decision making.The use of FDG-PET to target tumors by radiotherapy.Therapeutic implications of molecular imaging with PET in the combined modality treatment of lung cancer.State of the art radiation therapy for lung cancer 2012: a glimpse of the future.'Reconstruction: before or after postmastectomy radiotherapy?' A systematic review of the literature.Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients.Nodal recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: Incidence and proposed risk factors.The importance of patient characteristics for the prediction of radiation-induced lung toxicity.The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer.Effectiveness of surgery and individualized high-dose hyperfractionated accelerated radiotherapy on survival in clinical stage I non-small cell lung cancer. A propensity score matched analysis.Treatment with curative intent of stage III non-small cell lung cancer patients of 75 years: a prospective population-based study.International radiation oncology trainee decision making in the management of radiotherapy-induced nausea and vomiting.Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer.Can an FDG-PET/CT predict tumor clearance of the mesorectal fascia after preoperative chemoradiation of locally advanced rectal cancer?Total gross tumor volume is an independent prognostic factor in patients treated with selective nodal irradiation for stage I to III small cell lung cancer.18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: a planning study.Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study.The integration of PET-CT scans from different hospitals into radiotherapy treatment planning.False-positive FDG-PET scan due to brown tumours.Time trends in nodal volumes and motion during radiotherapy for patients with stage III non-small-cell lung cancer.Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).Is selective nodal irradiation in non-small cell lung cancer still safe when using IMRT? Results of a prospective cohort study.Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR).Hypoxia imaging with [¹⁸F]HX4 PET in NSCLC patients: defining optimal imaging parameters.Tumour delineation and cumulative dose computation in radiotherapy based on deformable registration of respiratory correlated CT images of lung cancer patients.Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer.Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: a prospective population-based study.Microscopic disease extension in three dimensions for non-small-cell lung cancer: development of a prediction model using pathology-validated positron emission tomography and computed tomography features.PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes.International patterns of practice in the management of radiation therapy-induced nausea and vomiting.Forward intensity-modulated radiotherapy planning in breast cancer to improve dose homogeneity: feasibility of class solutions.Feasibility of pathology-correlated lung imaging for accurate target definition of lung tumors.Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial.
P50
Q26859511-A7F50594-6F1C-4476-B1BB-0DF3588CB53BQ30993299-9CE79C64-256E-4681-AB1F-521DC17D4A4EQ34041735-FD9B861A-E668-4B6B-929E-8B17BF9356B7Q34392512-4FFAE801-22AE-4654-A755-4FBE21A4C3ECQ36350466-811AC121-E8E2-4AFC-84AB-D829DF555A4DQ36412502-FC27E446-F1C2-4D0A-99CD-E69F00419712Q36430990-C1883F9A-F1BD-49E4-AC5B-C50723F81244Q36950544-5DCE8ECA-23EF-4086-90D0-5EE770E43D0DQ37785001-10D6ADD8-1C94-4087-8809-0552DFB894CDQ37841907-A1084A61-F68C-40A6-BBD6-366B473F97BCQ38031320-9063A358-AAC3-40E7-8FB4-DA4F3E2191D6Q38244334-4176B87A-6146-4E6B-9A53-62A8CD705B5CQ38444389-46BD2E55-AC3A-4ED6-98D6-3CDF00C6A2C0Q39258951-38457956-43FB-4830-87FA-E8C5F01C7416Q40009969-33B9879B-BC67-405D-9D0A-EBE794DB6BD4Q43439474-09342F6D-832C-4DF6-A36C-E34BEF33BAF3Q43844220-6A13365E-7126-4F66-839A-F6E7223F70B5Q43901541-C106B2F8-588D-482B-8E7E-9AE683411433Q43924377-9120191A-6337-44A2-B86C-50770A8A46B9Q45247349-1FE32D0E-AF57-4B79-9B9C-66EBED4008BDQ46240822-81C2061E-1EFE-4BD3-89BE-A9F3807517DCQ46620840-1CF0D10A-9B5D-4A40-BDCF-EE35956167EEQ46700420-D26AB04F-1DD2-4A03-97D6-BA3CA822693AQ46712169-4907FA23-B161-463E-AD28-A8794ACEDB20Q46799527-8B16B8D5-9618-45D7-A6DB-0B8EDBC83BF9Q46872891-43DBBFD5-57B4-40A0-AA87-82D463FE62B9Q46904865-285A4D9E-7812-46AE-936E-4AA752198323Q48375192-F55E8DEB-B2AC-4261-BC68-DE39E4C8CEEDQ50474304-266AA17A-1E78-4314-8263-38D486916BA7Q50694848-4DA92B72-299A-421D-89D8-48DBF1ECB854Q50721242-8A31D03C-3EA1-45C0-9CFD-4C192219960EQ51625051-E6A0FE46-1D73-4F90-84A5-77DD68ED43F0Q51780811-0FC79649-8FA6-4CA7-B428-B7078EEB04C6Q51843234-13EDC5A1-26C4-4032-9B52-A18C86BCB3ADQ51897311-55AC36C3-D34E-4F89-8F6D-932E592C52DEQ51918577-2FFB2F5F-AEAF-4094-815D-D7F920B46364Q53128368-4D0AE7ED-0BDC-4D41-8990-01A0C39CE8E7Q53165030-A316EF06-0D08-4FED-B170-F13D863EC1FBQ53467935-ACE246FE-C380-4FCF-8EE4-483B61BC777AQ53521946-B2D987A0-C79F-423F-B153-768DB9D2EE8E
P50
name
Angela van Baardwijk
@ast
Angela van Baardwijk
@en
Angela van Baardwijk
@nl
type
label
Angela van Baardwijk
@ast
Angela van Baardwijk
@en
Angela van Baardwijk
@nl
prefLabel
Angela van Baardwijk
@ast
Angela van Baardwijk
@en
Angela van Baardwijk
@nl